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Alginate Lyase Exhibits Catalysis-Independent Biofilm Dispersion and
Antibiotic Synergy
John W. Lamppa,a* Karl E. Griswolda,b
Thayer School of Engineeringa and Molecular and Cellular Biology Program,b Dartmouth, Hanover, New Hampshire, USA

More than 2 decades of study support the hypothesis that alginate lyases are promising therapeutic candidates for treating mucoid Pseudomonas aeruginosa infections. In particular, the enzymes’ ability to degrade alginate, a key component of mucoid biofilm matrix, has been the presumed mechanism by which they disrupt biofilms and enhance antibiotic efficacy. The systematic
studies reported here show that, in an in vitro model, alginate lyase dispersion of P. aeruginosa biofilms and enzyme synergy
with tobramycin are completely decoupled from catalytic activity. In fact, equivalent antibiofilm effects can be achieved with
bovine serum albumin or simple amino acids. These results provide new insights into potential mechanisms of alginate lyase
therapeutic activity, and they should motivate a careful reexamination of the fundamental assumptions underlying interest in
enzymatic biofilm dispersion.

P

remature mortality among cystic fibrosis (CF) patients is typically associated with chronic airway infection by the opportunistic pathogen Pseudomonas aeruginosa (1). Upon colonization of the airway, P. aeruginosa causes a range of clinical
complications, including stimulation of a hyperinflammatory response, obstruction of the pulmonary tract, and progressive loss
of lung function (1–3). The bacterium’s persistence within the CF
lung is thought to result in large part from a biofilm mode of
growth (2, 4), which can subvert both the host immune response
and antibacterial therapies (5). In contrast to environmental
niches, in the CF lung, P. aeruginosa generally transitions to a
mucoid phenotype characterized by overproduction of the exopolysaccharide alginate (6). This copolymer of (1,4)-linked
␤-D-mannuronic acid and ␣-L-guluronic acid alters biofilm architecture and function (7) and thereby compounds P. aeruginosa’s
persistence in the chronically inflamed airway (5). Indeed, alginate is one of the most extensively studied P. aeruginosa virulence
factors (8).
Given alginate’s contribution to mucoid biofilm structure, its
function in bacterial virulence, and its role in the persistent nature
of lung infections, it has long been considered an attractive target
for interventional therapies (6). In particular, biocatalytic degradation of mucoid P. aeruginosa biofilms using alginate lyase enzymes (EC 4.2.2.3) has been the subject of more than 20 years of
research. Alginate lyase treatment has been shown to reduce viscosity in cultures of clinical isolates and in CF sputum (9, 10); it
strips biofilms from abiotic surfaces (11, 12), it enhances phagocytosis and killing of P. aeruginosa by human immune cells (13–
15), and it improves the efficacy of various antipseudomonal antibiotics (14, 16–19). In aggregate, these reports make a rather
convincing case for the use of inhaled alginate lyases for treating
chronic P. aeruginosa infections of the CF lung, although no clinical trials have been conducted to date.
In an effort to further bolster the rationale for therapeutic alginate lyases, we set out to conduct systematic studies analyzing the
solution phase kinetics, biofilm-disrupting potential, and antibiotic synergy of two promising enzyme candidates. Sphingomonas
sp. A1 alginate lyase (A1-III) has been shown previously to exhibit
high levels of activity toward bacterial alginate (20) and has also
been subjected to molecular engineering with an eye toward ther-
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apeutic applications (12, 21). P. aeruginosa alginate lyase (AlgL) is
produced by the CF-associated pathogen itself, and its confirmed
role in bacterial alginate biosynthesis (22, 23) suggests the enzyme
is an obvious choice for developing alginate-degrading CF biotherapies. On a superficial level, our results are entirely consistent
with the encouraging outcomes of prior alginate lyase studies. Our
systematic approach, however, has for the first time revealed that
enzyme-mediated biofilm disruption and antibiotic synergy are
decoupled from catalytic activity. The results described here suggest the need to carefully reexamine the veracity of fundamental
assumptions motivating interest in therapeutic alginate lyases.
MATERIALS AND METHODS
Bacterial strains. The mucoid P. aeruginosa clinical isolate FRD1 and its
nonmucoid derivative, SMC406, were obtained from the G. O’Toole laboratory (Geisel School of Medicine at Dartmouth, Hanover, NH).
SMC406 varies from FRD1 only in the deletion of the algT gene, which
effectively eliminates alginate biosynthesis (24). The Escherichia coli expression strain SHuffle T7 Express {fhuA2 lacZ::T7 gene1 [lon] ompT
ahpC gal att::pNEB3-r1-cDsbC (Specr lacIq) ⌬trxB sulA11 R(mcr-73::
miniTn10-Tets)2 [dcm] R(zgb-210::Tn10 –Tets) endA1 ⌬gor ⌬(mcrCmrr)114::IS10} was purchased from New England BioLabs (Ipswich, MA).
Cloning of the A1-III and AlgL alginate lyases. The alginate lyase gene
algL was amplified from the P. aeruginosa PAO1 genome using a 5= primer
with an ATG start codon, homology to base pairs 82 to 96 on the native
gene, and a 3= primer with either a TGA stop codon or a C-terminal
hexahistidine tag followed by a TGA stop codon. The amplified AlgL genes
were ligated into the pET28b expression vector and transformed into
electrocompetent SHuffle T7 Express. Individual clones were sequence
verified. Additionally, pET28b constructs containing either Sphingomonas sp. alginate lyase A1-III or a C-terminal hexahistidine-tagged variant
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(A1-III–His) (12) were transformed into SHuffle T7 Express, and individual clones were sequence verified.
The catalytically inactivated double point mutant of A1-III–His (A1DM-His) was constructed by targeting two of the active-site residues involved in the enzyme’s ␤-elimination mechanism (25). Mutation H188A
consisted of switching the histidine 188 GTG codon to a CGC codon,
while mutation Y242F replaced the tyrosine 242 GTA codon with a GAA
codon. The mutated gene was then ligated into the pET28b expression
vector and transformed into SHuffle T7 Express, and individual clones
were sequence verified.
Expression and purification of alginate lyases. Expression hosts were
grown overnight in 8 ml of LB supplemented with 30 g/ml kanamycin
(LB-KAN30) at 30°C. The overnight cultures were then subcultured 1:100
into 500 ml of fresh LB-KAN30 and grown to mid-log phase at 30°C, after
which the cells were equilibrated at 25°C for 30 min and then induced with
0.5 mM IPTG (isopropyl-␤-D-thiogalactopyranoside) for 21 h. Following
induction, the cell cultures were centrifuged at 6,000 ⫻ g at 4°C for 10 min,
and the total cell pellet for each construct was resuspended in 5 ml of
buffer A (20 mM NaH2PO4, pH 6.5). The resuspended pellets were transferred to 10-ml Pyrex beakers, equilibrated on ice for 20 min, and disrupted by sonication with 24 cycles of 10 s on and 10 s off (Fisher 550 Sonic
Dismembrator). Whole-cell lysate was centrifuged at 17,000 ⫻ g at 4°C for
20 min, and the soluble fraction was filtered through a 0.22-m polyethersulfone (PES) membrane.
Filtered soluble cell extract containing AlgL was loaded onto a 30-ml
hydroxyapatite column (Calbiochem, La Jolla, CA) equilibrated with buffer A. Buffer A continued to run for 10 ml at 2 ml/min before changing to
a step gradient of 30% buffer A and 70% buffer B (500 mM NaH2PO4, pH
6.5) for 60 ml, followed by 100% buffer B for an additional 65 ml. At 100%
buffer B, a single peak, containing AlgL and other proteins, was eluted.
This peak was dialyzed against 50 mM KH2PO4, 150 mM NaCl, pH 7, at
4°C and concentrated using a 10,000-molecular-weight cutoff (MWCO)
centrifugal filter. Concentrated sample (300 l) was then loaded onto a
120-ml Superdex75 size exclusion chromatography (SEC) (GE Healthcare Life Sciences, Piscataway, NJ) column equilibrated with 50 mM
KH2PO4, 150 mM NaCl, pH 7. Flow was maintained at 0.6 ml/min, and
purified AlgL was eluted as a single peak at 60 ml. Samples from the SEC
were concentrated using a 3,000-MWCO centrifugal filter and stored at
4°C. Enzyme purity was assessed by SDS-PAGE, and the final protein
concentrations were measured by A280 (NanoDrop 1000; Thermo Scientific,
Waltham, MA) using a molar absorptivity of 67,050 cm⫺1 M⫺1, estimated
with the VectorNTI software package (Invitrogen, Carlsbad, CA).
The same hydroxyapatite column and buffers were used to purify A1III enzyme from corresponding soluble cell extract. The column was
washed with buffer A for 20 ml at 2 ml/min, then increased to 5% B for 30
ml, increased again to 12% B for 50 ml, and finally 100% B for another 80
ml. An unresolved peak at 100 ml containing A1-III was collected and
dialyzed against 50 mM KH2PO4, 150 mM NaCl, pH 7 at 4°C before being
concentrated with a 10,000-MWCO centrifugal filter. Two hundred microliters of the concentrated sample was then loaded onto the same Superdex75 SEC column, and purified A1-III was eluted at 60 ml under the
same conditions described above. Samples did not require further concentration after SEC and were stored at 4°C. Enzyme purity was assessed
by SDS-PAGE, and the protein concentration was measured by A280 (molar absorptivity ⫽ 63,350 cm⫺1 M⫺1).
In addition to the above-mentioned purification protocol, single-step
immobilized metal ion affinity chromatography (IMAC) purification was
also used as an alternative method for isolating the His-tagged variants.
Briefly, 4 to 5 ml of filtered soluble cell extract was gently mixed with a
0.4-ml bed volume of nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qiagen, Valencia, CA), which had been equilibrated with native lysis buffer
(50 mM NaH2PO4, 300 mM NaCl, and 10 mM imidazole, pH 8.0). Binding occurred at 4°C for 1 h, with gentle rocking, after which the column
was drained and washed with 10 bed volumes of wash buffer (50 mM
NaH2PO4, 300 mM NaCl, and 20 mM imidazole, pH 8.0). Purified A1-III
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was eluted in a native elution buffer (50 mM NaH2PO4, 300 mM NaCl,
250 mM imidazole, pH 8.0), dialyzed into storage buffer (20 mM
NaH2PO4, pH 6.5), and kept at 4°C. Once again, enzyme purity was assessed by SDS-PAGE, and concentrations were determined by A280.
Enzyme kinetic analysis with soluble substrates. Enzyme-mediated
cleavage of the alginate carbohydrate backbone through beta elimination
results in formation of a C-4 –C-5 carbon-carbon  bond at the new
nonreducing termini, causing a strong absorbance peak at 235 nm. Replicate kinetic analysis was conducted by monitoring product formation at
235 nm in UV-transparent 96-well plates (Costar Fisher number 3635).
Using a multichannel pipette, 190-l aliquots of medium-viscosity brown
seaweed alginate (BSWA) (Sigma number A2033) were mixed thoroughly
with 10 l of enzyme residing in each well of the plate’s upper row. BSWA
dilutions were prepared in a reaction buffer (150 mM NaCl, 50 mM
NaH2PO4, pH 7.0) and ranged from 0.01% to 0.1% (wt/vol). Upon completion of mixing, the plate was transferred to a UV-visible plate reader
(SpectraMax 190; Molecular Devices, Sunnyvale, CA), and the formation
of product was tracked every 15 s over the course of 10 min. Initial slopes
from absorbance-versus-time plots were determined for each substrate
concentration, and nonlinear regression of the initial reaction rates versus
substrate concentration was used to determine apparent Vmax and Km
values for each enzyme. Kinetics with bacterial alginate substrate, purified
from P. aeruginosa FRD1 as described previously (26), followed the same
procedure (bacterial alginate follows the same cleavage mechanism as
BSWA).
Biofilm cell viability assays. P. aeruginosa strains FRD1 and SMC406
were grown on LB agar plates at 37°C. Single colonies were selected and
used to inoculate 3-ml cultures of tryptic soy broth (TSB). The cultures
were placed on an orbital shaker for 21 h at 37°C before being diluted
1:1,000 in fresh TSB. Upon dilution, the cultures were aliquoted into
96-well minimum biofilm eradication concentration (MBEC) plates (Innovotech, Edmonton, AB, Canada) at a volume of 75 l per well. The
corresponding peg lid was then placed on top of the plate, and the sides of
the plate were sealed with strips of Breathe-Easy membrane (Diversified
Biotech, Dedham, MA), which eliminated evaporation but still allowed
gas permeability. The plates were incubated statically at 37°C for 20 h
before the peg lids were removed, rinsed in sterile deionized water for 10
s, and placed into black, clear-bottom, 96-well treatment plates (Corning,
Lowell, MA). The treatment plates contained 125 l of activity buffer (50
mM potassium phosphate, 150 mM NaCl, pH 7) only (untreated) or with
one of the following agents: 100 or 500 g/ml tobramycin (MP Biomedicals, Solon, OH), 1,000 g/ml protein (A1-III–His, A1-DM-His, A53CHis-PEG [polyethylene glycol], AlgL-His, or bovine serum albumin
[BSA]), the constituent amino acids of A1-III–His at the same molar
concentrations contained in 1,000 g/ml of intact enzyme, the arginine
constituent of A1-III–His at the same molar concentration contained in
1,000 g/ml of the intact enzyme, or arginine at the same molar concentration as the sum total of all amino acids in 1,000 g/ml A1-III–His.
Additionally, 100 or 500 g/ml of tobramycin was combined with each of
the protein and amino acid treatments to assess synergistic effects. The
treatment plates were sealed with strips of Breathe-Easy membrane and
statically incubated at 37°C for 12 h.
After treatment, the peg lids were removed from the treatment plates,
rinsed in sterile deionized water for 10 s, and placed into black, clearbottom, 96-well plates containing 125 l per well of alamarBlue (Invitrogen, Carlsbad, CA) to measure biofilm cell viability. Concurrently, alamarBlue was added to the treatment plates to measure the viability of any
detached cells. All alamarBlue plates were sealed with Breathe-Easy membranes and statically incubated for 12 h at 37°C. Membranes and peg lids
were then removed, and reduction of the alamarBlue resazurin compound was measured by fluorescence at an excitation wavelength of 540
nm (550-nm cutoff) and an emission wavelength of 585 nm. Additionally,
alamarBlue background signal was measured in the presence of all treatments without cells and subtracted from the cell viability signal.
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FIG 1 SDS-PAGE analysis of alginate lyase expression and purification. (A) P. aeruginosa AlgL. Lane 1, Bio-Rad Precision Plus Dual Color Standard; lane 2, AlgL
soluble cell-free extract; lane 3, AlgL-His soluble cell-free extract; lane 4, AlgL eluted from hydroxyapatite; lane 5, AlgL-His eluted from hydroxyapatite; lane 6,
AlgL following size exclusion chromatography; lane 7, AlgL-His following size exclusion chromatography. (B) Sphingomonas sp. A1-III. Samples containing the
native and His-tagged proteins were loaded as for panel A.

SEM. Polystyrene peg lids were prefixed in 0.1 M PIPES [piperazineN,N=-bis(2-ethanesulfonic acid)], pH 7, containing 50 mM L-lysine,
0.075% ruthenium red, and 2.5% glutaraldehyde for 30 min at room
temperature. The peg lids were then fixed in 0.1 M PIPES, pH 7, containing 0.075% ruthenium red and 2.5% glutaraldehyde for 3 h at room temperature before being rinsed with 0.1 M PIPES, pH 7, for 20 min (the rinse
was repeated three times). Dehydration of the peg lids was performed in
30%, 50%, 70%, and 95% ethanol for 5 min each, with 2 final changes in
100% ethanol for 5 min each. The peg lids were then air dried in a desiccator for 72 h. Upon completion of air drying, individual pegs were
snapped off from the lids with tweezers and mounted on scanning electron microscopy (SEM) stubs with a layer of melted apiezon wax. The
mounted pegs were then sputter coated with gold and palladium and
viewed by SEM (XL30 ESEM FEG; FEI, Hillsboro, OR).
Statistical analysis. Statistical significance was assessed using one-way
analysis of variance (ANOVA) and post hoc Tukey’s multiple-comparison
tests. Significance was determined at an ␣ value of 0.05.

RESULTS

Selection, cloning, and production of alginate lyases. We selected two enzyme candidates for comparative analysis. Sphingomonas sp. A1-III has been reported to exhibit particularly high
levels of activity toward bacterial alginate (20) and has been the
subject of extensive study and preclinical development (9, 12, 21).
P. aeruginosa AlgL has naturally evolved to degrade bacterial alginate, and the enzyme was shown previously to facilitate detachment of P. aeruginosa from biofilms (27). The algL gene was amplified from P. aeruginosa PAO1 genomic DNA, cloned into the
pET28b expression vector, and transformed into electrocompetent E. coli SHuffle T7 Express. A gene encoding a variant of AlgL
bearing a C-terminal hexahistidine tag (AlgL-His) was constructed in a similar manner. Shake flask cultures of the two expression strains were induced overnight, and the proteins were
purified from whole-cell lysates via hydroxyapatite and then SEC.
The yields were 0.39 mg/liter for native AlgL and 2.3 mg/liter for
AlgL-His, with both proteins exhibiting ⬎90% purity (Fig. 1A).
The synthesis and cloning of genes encoding the native A1-III
enzyme and its C-terminal His-tagged variant have been described previously (12). Expression and purification of A1-III and
A1-III–His followed the same procedures described for AlgL
above. The final yields for the two proteins were 9.3 mg per liter of
bacterial culture and 15 mg per liter of culture, respectively, and
again, both proteins were ⬎90% pure following SEC (Fig. 1B).
In addition to the two-step hydroxyapatite and SEC purification described above, the His-tagged variants AlgL-His and A1-
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III–His were purified by one-step IMAC nickel chromatography.
IMAC purification resulted in 7.6 mg AlgL-His per liter of bacterial culture and 13 mg A1-III–His per liter of culture. The purity of
the proteins eluted from the IMAC resin was comparable to that
obtained with the two-step purification (data not shown). It bears
noting that the IMAC yields for AlgL-His were at least 3-fold
greater than any previously reported purification of the enzyme
from shake flask cultures (28, 29). Importantly, kinetic analysis
(described below) showed that the IMAC-purified proteins were
indistinguishable from samples prepared by two-step chromatography.
Solution phase enzyme kinetics. Intuition suggests that the
therapeutic potential of alginate lyase enzymes should be directly
proportional to their catalytic firepower, and therefore, the solution phase kinetics of alginate degradation were used to compare
the prospective utilities of the various enzymes (Table 1). Initial
studies were conducted with commercially available BSWA, a
standard substrate for analysis of alginate lyase activity. In comparing the two native enzyme constructs, A1-III exhibited a 10fold greater Vmax than AlgL, but the difference in Km values was
not statistically significant. With the BSWA substrate, the Vmax
and Km values for the native A1-III enzyme were similar to those of
the His-tagged analog A1-III–His, as were the respective values for
AlgL and AlgL-His. Thus, appending a C-terminal hexahistidine
tag onto either of the two alginate lyases did not substantially alter
their solution phase kinetics.
BSWA is a readily available commodity product commonly
used for characterizing alginate lyase activity, but the ultimate
therapeutic target is alginate produced by the bacterium P. aerugi-

TABLE 1 Pseudo Michaelis-Menten kinetic parameters with BSWA and
bacterial (FRD1) alginate substrates
Enzyme

Substrate

Vmax
[⌬A235 (min · mg)⫺1]

Km (g/ml)

Vmax/Km

AlgL

BSWA

26 ⫾ 1

70 ⫾ 10

0.36 ⫾ 0.05

AlgL-His

BSWA
FRD1

35 ⫾ 2
127 ⫾ 6

40 ⫾ 10
840 ⫾ 70

0.8 ⫾ 0.2
0.15 ⫾ 0.01

Al-III

BSWA

290 ⫾ 20

39 ⫾ 9

8⫾2

Al-III–His

BSWA
FRD1

337 ⫾ 9
310 ⫾ 10

100 ⫾ 10
420 ⫾ 40

3.4 ⫾ 0.4
0.74 ⫾ 0.08
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FIG 2 Analysis of cell viability in P. aeruginosa biofilms following alginate lyase treatments. (A) Mucoid FRD1 biofilms were treated for 12 h with either 500
g/ml tobramycin (Tob), 1,000 g/ml alginate lyase, or a combination thereof. Subsequently, cell viability was quantified with alamarBlue, and the results were
normalized to untreated biofilms. (B) Nonmucoid SMC406 biofilms were treated in the same manner as for panel A, except that tobramycin concentrations were
lowered to 100 g/ml. The error bars represent standard deviations from four replicates. Statistically significant (␣ ⫽ 0.05) differences relative to untreated
biofilms are marked with asterisks.

nosa. Bacterial alginate differs from BSWA in its relative mannuronic and guluronic acid content, as well as the presence of acetyl
esters on C-2 and C-3 hydroxyl groups (30). To compare the activities of the two enzymes on a more clinically relevant substrate,
the kinetics of A1-III–His and AlgL-His were determined with
alginate purified from P. aeruginosa strain FRD1, a mucoid clinical isolate (Table 1). The Vmax value for A1-III–His was essentially
unchanged compared to its value with the BSWA substrate, but
the enzyme’s Km for bacterial alginate was at least 4-fold higher.
Thus, A1-III–His exhibited strong activity toward both BSWA
and bacterial alginate, but it required substantially higher concentrations of the latter to achieve maximum rates of degradation.
The AlgL-His enzyme, on the other hand, was found to have a
significant increase in both Km (20-fold) and Vmax (3.6-fold) when
comparing the bacterial substrate to BSWA. The P. aeruginosa
enzyme, therefore, achieves higher maximum rates of degradation
with its native bacterial substrate, but analogous to A1-III–His, it
requires concentrated substrate solutions to do so. Despite the
increased activity of AlgL-His toward its native substrate, the A1III–His enzyme maintained a significant advantage with respect to
the maximum degradation rates of bacterial alginate (⬎2-fold). In
contrast, the catalytic efficiencies (Vmax/Km) of the two enzymes
were not significantly different for the therapeutically relevant
substrate.
Treatment of mucoid and nonmucoid biofilms with A1-III–
His and tobramycin. Within the hydrogel environment of bacterial biofilms, one may reasonably assume that the local concentrations of alginate will be quite high. Under conditions of high
substrate concentration, Vmax, as opposed to Vmax/Km, is the most
relevant kinetic parameter. We therefore elected to examine only
A1-III–His in the initial biofilm assays. While we had previously
validated the biofilm-disrupting potential of A1-III–His using lectins to quantify alginate in enzyme-linked immunosorbent assay
(ELISA)-type assays (12), here, we sought to quantify bactericidal
activity within established biofilms. The alamarBlue reagent had
been validated previously as an accurate reporter of P. aeruginosa
viability in both planktonic cultures and biofilms (31). Thus, alamarBlue was used to monitor relative viability in the subsequent
studies.
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Treatment of mucoid FRD1 biofilms with 500 g/ml of tobramycin, a clinically relevant concentration (32), resulted in a 48%
reduction in cell viability compared to untreated controls (Fig.
2A). Standalone treatment with 1,000 g/ml of A1-III–His
showed a 40% reduction in alamarBlue signal, which likely resulted from enzyme-mediated cellular detachment as opposed to
direct bactericidal action. In contrast, the combination of the two
treatments (500 g/ml tobramycin with 1,000 g/ml of A1-III–
His) repeatedly resulted in complete elimination of viable cell signal. Given the exceptional efficacy of the combined treatment on
FRD1 biofilms, a simple control study was designed to confirm
that the synergistic effect was a function of alginate degradation.
Specifically, the treatment study with tobramycin and A1-III–His
was repeated using the isogenic, nonmucoid P. aeruginosa strain
SMC406 (Fig. 2B). The tobramycin treatment, lowered to 100
g/ml to account for the greater sensitivity of nonmucoid strains
(7), failed to reduce viable cells in the biofilm to a statistically
significant degree. Surprisingly, the standalone A1-III–His treatment reduced alamarBlue signal by 40%, the same as observed
with FRD1. Also similar to the results with FRD1, the combination treatment reduced SMC406 cell viability to background levels. These results were unanticipated, as the SMC406 strain does
not produce alginate and should therefore be unaffected by alginate lyase treatment.
Given the unexpected results with the nonmucoid SMC406
strain, studies were designed to more rigorously assess the role of
alginate degradation in FRD1 biofilm disruption. Based upon an
X-ray crystal structure and a hypothesized mechanism (25), an
active-site double mutant (H188A and Y242F) of A1-III–His was
constructed (here, the double mutant is referred to as A1-DMHis). The A1-DM-His protein was expressed and purified at levels
comparable to A1-III–His, but the purified double mutant exhibited no detectable activity on BSWA, even at enzyme concentrations 40-fold higher than those used to characterize the active
biocatalyst (data not shown). The inactive A1-DM-His enzyme
was used to treat both mucoid FRD1 and nonmucoid SMC406
biofilms alone and in combination with tobramycin (Fig. 2). As a
single-agent treatment, A1-DM-His reduced biofilm signals by
25%, whereas in combination with tobramycin, it reduced biofilm
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FIG 3 Analysis of P. aeruginosa viability following biofilm treatments. Mucoid FRD1 biofilms were treated for 12 h with a panel of biologic reagents, tobramycin,
or combinations thereof. alamarBlue was then used to quantify cell viability in the remaining adherent biofilm (black bars), as well as in the treatment supernatant
containing detached planktonic cells (white bars). (A) A1-DM-His alginate lyase and BSA were used to assess the effects of protein treatments that lacked
alginate-degrading activity. (B) Treatments consisting of individual amino acids were used to assess whether higher-order protein structure was required for
tobramycin synergy. The treatments were composed of (i) A1-III–His AA, with each individual amino acid at the same concentration as its specific molar
contribution to 1,000 g/ml intact A1-III–His; (ii) A1-III–His Arg, with arginine at the same concentration as its specific molar contribution to 1,000 g/ml
intact A1-III–His; and (iii) arginine, with arginine at the same molar concentration as the total of all individual amino acids in 1,000 g/ml intact A1-III–His. (C)
Treatment with diverse alginate lyase enzymes was used to assess the effects of varied catalytic activity and proteolytic sensitivity. A1-III–His was repeated as a
positive control. AlgL-His was included as a reduced-activity enzyme evolved to function specifically on bacterial alginate. A53C-His-PEG is a genetically
engineered and PEGylated variant of A1-III–His that exhibits nearly identical solution phase kinetics but should have greater resistance to proteolytic degradation. The error bars represent standard deviations from six replicates. For biofilm cells, statistically significant (␣ ⫽ 0.05) differences relative to untreated biofilm
are marked with asterisks. For planktonic cells, statistically significant (␣ ⫽ 0.05) differences relative to untreated biofilm are marked with pound signs.

cell signals to background levels. The latter result was indistinguishable from those achieved with the wild-type enzyme and
tobramycin combination. Thus, it was concluded that A1-III–His
antibacterial synergy with tobramycin was decoupled from catalytic activity.
Treatment of mucoid biofilms with proteins lacking alginate-degrading activity. While the above-mentioned results
demonstrated that catalytic activity was irrelevant to biofilm dispersion and tobramycin synergy, they did not rule out the possibility that the observed antibiofilm effects resulted from some
other molecular feature specific to the A1-III alginate lyase protein. To test this hypothesis, the FRD1 biofilm studies were repeated with the inactive A1-DM-His enzyme, as well as BSA as a
sham treatment (Fig. 3A). In addition to analyzing cell viability
within the treated biofilms, viable cells were also quantified in the
treatment supernatant itself. Thus, the new studies captured the
treatment effects on both adherent and detached cell populations.
BSA treatment affected neither biofilm nor planktonic alamarBlue
signal. When used in combination with tobramycin, however,
BSA essentially eradicated viable cells from both the planktonic
and biofilm states. Likewise, A1-DM-His combined with tobramycin again eradicated the biofilm cells (consistent with the results shown in Fig. 2A) and left few viable cells in the planktonic
state. In aggregate, these results indicated that the observed tobramycin synergy was not a function of any specific alginate lyase
property but was more likely a nonspecific phenomenon stemming from biofilm exposure to proteins in general.
Amino acid treatment of mucoid biofilms. In an effort to assess whether intact primary/secondary/tertiary protein structure
was required for antibiofilm synergy with tobramycin, a panel of
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individual amino acid mixtures was examined next. Each treatment was based on the molar concentration of the individual constituent amino acids in 1,000 g/ml intact A1-III–His. Treatment
with either the full complement of constituent amino acids (A1III–His AA) or just the constituent arginines of A1-III–His (A1III–His Arg) did not affect the biofilm cell signal but did increase
the planktonic cell signal (Fig. 3B). Treatment with arginine at a
molar concentration equal to that of the sum total of all individual
constituent amino acids (arginine) yielded a 2-fold increase in the
biofilm signal and a 5-fold increase in the planktonic cell signal.
These observations suggest that the amino acids were used as a
nutrient source in the otherwise nutrient-depleted buffer, and
they are also consistent with the prior use of arginine as a growth
supplement for P. aeruginosa biofilms (33). As observed in the
earlier trials, tobramycin alone yielded only a moderate reduction
in cell viability (36% for biofilm and 26% for planktonic cells). In
combination with tobramycin, however, each of the amino acid
treatments resulted in complete knockdown of the biofilm cell
signal. The combined treatments were found to retain some level
of planktonic cell viability, but the levels were at least 55% lower
than those observed with tobramycin treatment alone. Thus,
amino acid mixtures were as good as or even better than intact
proteins with respect to bactericidal synergy toward biofilm cells.
Alginate lyase proteolytic sensitivity as a parameter in mucoid biofilm treatments. The above-mentioned results suggested
that the alginate lyase treatments manifested antibiotic synergy by
virtue of their consumption as a nutrient source, which would
necessitate proteolytic degradation of the enzymes. As a preliminary test of this hypothesis, mucoid biofilms were treated with an
active alginate lyase that had been conjugated to a 20-kDa poly-
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FIG 4 Representative SEM images of FRD1 biofilms treated with buffer only (A), A1-III–His (B), A1-DM-His (C), A53C-His-PEG (D), A1-III–His AA (E), or
BSA (F). The distinct architecture of biofilm matrix versus simple adherent cells is clear in panel A compared to panel B, C, D, or F.

ethylene glycol chain, i.e., PEGylated. PEGylation is a well-validated method of reducing the proteolytic susceptibility of proteins
(34, 35), and the PEGlyated alginate lyase (A53C-His-PEG) had
been shown previously to exhibit wild-type solution phase kinetics and better than wild-type biofilm disruption (12). Treatment
of mucoid biofilms with A1-III–His once again showed a decreased biofilm cell signal and at the same time an increased
planktonic cell signal, which is consistent with enzyme-mediated
detachment of biofilm cells (Fig. 3C). Similar to earlier results,
A1-III–His combined with tobramycin essentially eradicated biofilm cells. Interestingly, treatment with AlgL-His alone caused an
increase in both the biofilm cell signal and the planktonic cell
signal. A combination of AlgL-His and tobramycin, however,
yielded the expected knockdown of bacterial viability. Similar to
AlgL alone, treatment with only A53C-His-PEG resulted in both
increased biofilm cell signal and planktonic cell signal. In sharp
contrast to all other combination treatments, however, A53CHis-PEG with tobramycin was no different than tobramycin
alone. Thus, the PEGylated alginate lyase was the only biological
treatment that failed to exhibit synergy with tobramycin.
Analysis of treatments by SEM. The alamarBlue assays of cell
viability consistently pointed to a catalysis-independent mode of
action for the alginate lyases, but to corroborate these results, the
biofilm treatment studies were repeated and SEM was used to
visualize treated biofilms in a direct fashion. Importantly, preSEM alamarBlue testing of these biofilms gave results matching
those from the initial studies described above (data not shown).
Representative images at ⫻8,000 magnification (Fig. 4) highlight
the differential effects of various treatments with respect to biofilm architecture, total biomass, and vitality of adherent cells.
Blank buffer treatment of biofilms resulted in bacterial cells embedded within robust and copious extracellular matrix. In the
absence of tobramycin, treatment with A1-III–His or A1-DM-His
caused the nearly complete removal of extracellular matrix. As
single agents, A53C-His-PEG and BSA also appeared to remove
the majority of biofilm matrix, but each appeared to subtly increase the number of attached cells compared to biofilms treated
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with the wild-type A1-III–His enzyme. Importantly, the qualitative SEM analysis of matrix removal by A1-III–His and A53C-HisPEG showed good agreement with prior quantitative analysis
based on binding of an alginate-sensitive lectin (12). In contrast to
the intact proteins, treatment with the constituent amino acids
resulted in only partial removal of the biofilm matrix and a dramatic increase in the density of attached cells. Following treatment
with biological agents, the bacteria generally appeared to have
intact structure and regular shape, although some deviations from
normal morphology were seen with the A53-His-PEG standalone
treatment (Fig. 4D).
SEM analysis of biofilms treated with combinations of tobramycin and biologics again showed that the biological agents contributed to a reduction in extracellular matrix. Compared to the
results from biological agents alone, the only differences were that
the amino acid treatment with tobramycin left no identifiable matrix (compare Fig. 4E and 5E) while A53C-His-PEG with tobramycin yielded more matrix than the enzyme alone (compare Fig.
4D and 5D). More striking was the effect of tobramycin treatments on cellular integrity. As a single agent, the antibiotic yielded
a subpopulation of adherent cells with atypical membrane morphology (Fig. 5A). The combination of tobramycin with A53CHis-PEG yielded largely similar results (Fig. 5D). In contrast, few
if any intact adherent cells could be identified from biofilms
treated with combinations of tobramycin and A1-III–His, A1DM-His, BSA, or A1-III–His AA; only ghost cells were observed
(Fig. 5B, C, E, and F).
Overall, SEM imaging correlated well with the results of
alamarBlue viability analysis. One apparent discrepancy was the
A53C-His-PEG treatment versus the PBS control. The quantitative alamarBlue studies showed that biofilms treated with the
PEGylated enzyme exhibited almost 2-fold-higher signals than
those treated with PBS. The SEM images, on the other hand, suggest a dramatic reduction in total biomass upon treatment with
A53C-His-PEG. It is important to note that the alamarBlue reagent measures cellular metabolic activity, and it is therefore insensitive to biofilm matrix components, which constitute a sub-
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FIG 5 SEM images of FRD1 biofilms treated with tobramycin (A), tobramycin and A1-III–His (B), tobramycin and A1-DM-His (C), tobramycin and
A53C-His-PEG (D), tobramycin and A1-III–His AA (E), or tobramycin and BSA (F).

stantial fraction of the biomass seen in PBS-treated biofilms (Fig.
4A). Moreover, as noted above, some fraction of cells from A53CHis-PEG-treated biofilms exhibited anomalous morphology (Fig.
4D). This atypical morphology might correlate with altered cellular metabolic activity, which could in turn impact the alamarBlue
assay. Together, these observations might explain the apparent
discrepancy between alamarBlue and SEM analyses of A53C-HisPEG- versus PBS-treated biofilms.
DISCUSSION

P. aeruginosa’s persistence in the CF airway can, to a large extent,
be attributed to the bacterium’s biofilm mode of growth (36).
Additionally, P. aeruginosa’s transition to a mucoid phenotype in
the majority of CF patients (1) leads to alginate-rich biofilms and
enhanced antibiotic resistance (7). Therefore, disruption of the
mucoid biofilm architecture with alginate lyases has long been
considered a promising approach for enhancing antibiotic efficacy (16), and recent studies support this hypothesis (17, 19). In
contrast, at least one report showed that exogenously added Azotobacter vinelandii alginate lyase failed to remove mucoid P.
aeruginosa biofilms despite the enzyme’s confirmed activity toward the alginate substrate (37). One explanation for such an outcome is that the alginate biopolymer has a negligible contribution
to mucoid biofilm adhesion (38). Regardless, the apparent disconnect between reports of alginate lyase antibiotic synergy versus
enzyme-mediated biofilm disruption motivated the design of systematic studies to more fully assess the antibacterial potential of
these biocatalysts.
Alginate lyase A1-III–His was selected over AlgL-His for the
initial biofilm cell viability assays as a result of the enzyme’s
superior alginate degradation kinetics. SEM analysis showed
that A1-III–His drastically reduced extracellular matrix compared to untreated and tobramycin-treated biofilms. Additionally, cotreatment of biofilms with A1-III–His and tobramycin
demonstrated a vast improvement in cell killing compared to no
treatment or tobramycin-only treatment. These results are consis-
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tent with a long series of prior reports demonstrating cooperativity between alginate lyases and antibiotics (14, 16–18). Surprisingly, equivalent results were obtained in controlled studies with
an isogenic nonmucoid strain that does not produce alginate exopolysaccharide. Although not peer reviewed, a recent report
from the University of British Columbia found similar results with
the nonmucoid P. aeruginosa strain PAO1 (39), which also fails to
produce alginate under typical growth conditions (40). These observations suggested that alginate lyase catalytic activity was not a
requisite factor for biofilm disruption or synergy with the antibiotic tobramycin. To test this hypothesis, we repeated our biofilm
cell viability assays with the genetically inactivated alginate lyase
A1-DM-His, as well as BSA sham treatments. Both catalytically
inactive proteins yielded SEM evidence of biofilm dispersion and
exhibited enhanced killing of biofilm cells when used in combination with tobramycin. Thus, biofilm dispersal and increased antibiotic efficacy appear to be nonspecific effects manifested by proteins in general. While early reports showed that heat-treated
alginate lyase improved macrophage uptake of P. aeruginosa (15),
the results reported here represent the first direct evidence that
alginate lyase catalytic activity is superfluous to biofilm disruption
and antibiotic synergy.
An alternative explanation for the antibiofilm effects of alginate lyases could be related to enzyme-mediated changes in cell
physiology. Indeed, there is evidence that the growth behavior of
P. aeruginosa and other biofilm-associated cells is a greater contributor to antibiotic resistance than any physical barrier the biofilm matrix might provide (41, 42). Nutrient limitation within
biofilm communities leads to a general reduction in cellular metabolism (43), as well as specific response mechanisms that increase antibiotic tolerance (44). Another key piece of the puzzle is
that P. aeruginosa biofilms can be dispersed by sudden increases in
carbon source availability (45), and it has been shown that this
effect depends upon protein synthesis (46). Additionally, arginine
treatment is thought to upregulate the metabolism of P. aeruginosa in anaerobic biofilms, and it thereby increases antibiotic ef-
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ficacy by 10- to 100-fold (47). Thus, even simple nutrients have
the potential to profoundly influence adherent cell behavior
and/or modulate antibiotic efficacy toward biofilms.
These insights motivated a hypothesis that, as opposed to actively degrading biofilm matrix, alginate lyases were acting as a
nutrient source, modulating cellular metabolism and thus inducing cellular detachment and enhancing tobramycin efficacy. To
test this hypothesis, biofilms were treated with the individual
amino acid components of A1-III–His alginate lyase. With respect
to enhancing tobramycin efficacy, the amino acid cotreatments
matched the effectiveness of the intact enzyme. In the absence of
tobramycin, however, SEM imaging showed the amino acid treatments failed to completely remove biofilm matrix surrounding
the adherent cells. This contrasted with the intact A1-III–His, A1DM-His, or BSA treatment, each of which individually resulted in
complete erosion of the biofilm matrix. A potential explanation
for the observed differences in the dispersive potential of intact
proteins versus constituent amino acids relates to bioavailability.
During infection, bacteria encounter nutrient-depleted environments and secrete proteases that can, through various mechanisms, facilitate degradation of host proteins for use as a nutrient
source (48, 49). At the same time, several secreted pseudomonal
proteases have been implicated in the degradation of structural
proteins or adhesins that contribute to biofilm formation (50, 51).
Together, these facts suggest a nonintuitive mechanism for the
antibiofilm effects of alginate lyases: (i) biofilm bacteria sense the
intact protein treatments and in response secrete proteases, (ii)
subsequent assimilation of the freed amino acids upregulates cellular metabolism and renders the bacteria more susceptible to
killing by tobramycin, and (iii) the secreted proteases destabilize
key components of the biofilm matrix and initiate biofilm dissolution. Although this mechanism is speculative in nature, the literature supports each postulate independently, and their proposed connectivity is consistent with the observations reported
here.
The above hypothesis was tested in a preliminary fashion by
treating mucoid biofilms with the A53C-His-PEG alginate lyase,
whose pendent 20-kDa PEG chain should at least partly shield the
protein from proteases. Consistent with prior reports of the enzyme’s ability to disrupt mucoid biofilms (12), SEM imaging revealed that A53C-His-PEG itself caused nearly complete dissolution of the biofilm matrix. The above-described mechanism
would predict this outcome, if indeed the bacteria sensed the enzyme and subsequently secreted proteases. In contrast to all other
intact protein treatments, however, a combination of A53C-HisPEG with tobramycin was no more effective at killing than treatment with tobramycin alone. Again, this is consistent with the
proposed mechanism, if tobramycin synergy is ultimately dependent on the presence of individual amino acids, which are less
readily liberated from the PEGylated enzyme. As a corollary, direct treatment of biofilms with constituent amino acids manifests
a less pronounced degradation of biofilm matrix but fully replicates the intact proteins’ synergy with tobramycin. Regardless of
the mechanistic details, the studies reported here demonstrate
that protein treatments nonspecifically promote P. aeruginosa
biofilm dispersal, and they may enhance tobramycin efficacy
through the action of their constituent amino acids.
Taken together, the above results reveal that complete biofilm
dispersal is neither sufficient nor required for tobramycin synergy
with biological cotreatments. Importantly, the results disclosed
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here do not contradict prior reports of therapeutically relevant
activity among alginate lyases. Indeed, they reinforce the widely
published conclusions that this class of enzymes manifests biofilm-dispersive properties and synergy with antibiotics, yet the
current studies are the first to probe the mechanism underlying
these effects. In the biofilm model used here, alginate lyase catalytic activity is irrelevant to biofilm dispersion and tobramycin
synergy. In fact, equivalent disruption of the biofilm matrix is
achieved with the commodity protein BSA, and equivalent tobramycin synergy is achieved with either BSA or simple amino acids.
While further work is required to extend the current studies to
more clinically relevant models, it is clear that the long history of
alginate lyase enzyme therapies should be reexamined with a more
critical eye. In particular, the motivating assumption that enzymatic degradation of alginate would drive therapeutic effects may
well be unfounded.
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